


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition useful in treating ~~cancer or inflammation~~ cancer, inflammation or a hyperproliferative disorder in a human, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent or excipient and a compound of formula (I):



wherein:

a is 0 to 4;

R¹ is carbocyclyl or heterocyclyl;

each R² is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -R⁹-N=N-O-R⁸, -S(O)_pR⁷ (where p is 0 to 2), and -S(O)_pN(R⁷)₂ (where p is 0 to 2);

R³ and R⁴ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)N(R⁷)₂,

$-N(R^7)C(O)R^7$, $-R^9-N=N-O-R^8$, $-S(O)_pR^7$ (where p is 0 to 2), and $-S(O)_pN(R^7)_2$
(where p is 0 to 2);

R^5 and R^6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkenyl and heterocyclalkyl;
each R^7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl; and

R^9 is a bond or a straight or branched alkylene or alkenylene chain;


as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or as a solvate or polymorph; or as a pharmaceutically acceptable salt thereof,

with the proviso that R^1 can not be unsubstituted phenyl when all of the following occur:

- (i) a is 2 and one R^2 is methoxy in the 6-position of the isoquinolone ring and the other R^2 is methoxy in the 7-position of the isoquinolone ring; and
- (ii) R^3 , R^5 and R^6 are all hydrogen, and
- (iii) R^4 is 3,4-dimethoxybenzyl.

2.-39. (Cancelled)

40. (Currently Amended) A method of treating ~~cancer~~ cancer, inflammation or a hyperproliferative disorder in a mammal, which method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):



wherein:

a is 0 to 4;

R¹ is carbocyclyl or heterocyclyl;

each R² is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)R⁷, -R⁹-N=N-O-R⁸, -S(O)_pR⁷ (where p is 0 to 2), and -S(O)_pN(R⁷)₂ (where p is 0 to 2);

R³ and R⁴ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)R⁷, -R⁹-N=N-O-R⁸, -S(O)_pR⁷ (where p is 0 to 2), and -S(O)_pN(R⁷)₂ (where p is 0 to 2);

R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkenyl and heterocyclylalkyl;
 each R⁷ is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl; and

R^9 is a bond or a straight or branched alkylene or alkenylene chain;
as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or as a solvate or polymorph; or as a pharmaceutically acceptable salt thereof.


41. (Cancelled)

42. (Currently Amended) The method according to ~~any one of Claim 40 or 41~~ wherein the cancer or inflammation is associated with hyperproliferation or cell survival.

43. (Currently Amended) The method according to ~~any one of Claim 40 or 41~~ wherein the hyperproliferative disease, cancer or inflammation is associated with the activity of SGK.

44. (Cancelled)

45. (Original) A method of treating a mammal having a disorder or condition associated with hyperproliferation and cell survival, wherein said method comprises administering to the mammal having the disorder or condition a therapeutically effective amount of a compound of formula (I):



wherein:

a is 0 to 4;

R^1 is carbocyclyl or heterocyclyl;

each R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, $-OR^7$, $-C(O)OR^7$, $-C(O)N(R^7)_2$, $-N(R^7)_2$, $-N(R^7)C(O)N(R^7)_2$, $-N(R^7)C(O)OR^8$, $-N(R^7)C(O)R^7$, $-R^9-N=N-O-R^8$, $-S(O)_pR^7$ (where p is 0 to 2), and $-S(O)_pN(R^7)_2$ (where p is 0 to 2);

R^3 and R^4 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, $-OR^7$, $-C(O)OR^7$, $-C(O)N(R^7)_2$, $-N(R^7)_2$, $-N(R^7)C(O)N(R^7)_2$, $-N(R^7)C(O)OR^8$, $-N(R^7)C(O)R^7$, $-R^9-N=N-O-R^8$, $-S(O)_pR^7$ (where p is 0 to 2), and $-S(O)_pN(R^7)_2$ (where p is 0 to 2);

R^5 and R^6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkenyl and heterocyclylalkyl;

each R^7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl;


each R^8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl; and

R^9 is a bond or a straight or branched alkylene or alkenylene chain;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or as a solvate or polymorph; or as a pharmaceutically acceptable salt thereof.

46. (Currently Amended) The method according to ~~any one of Claims 40-45~~
Claim 40 or Claim 45 wherein the mammal is a human.

47. (Original) A method of treating a mammalian cell with a compound of
 formula (I):



wherein:

a is 0 to 4;

R¹ is carbocyclyl or heterocyclyl;

each R² is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)R⁷, -R⁹-N=N-O-R⁸, -S(O)_pR⁷ (where p is 0 to 2), and -S(O)_pN(R⁷)₂ (where p is 0 to 2);

R³ and R⁴ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, aralkenyl, halo, haloalkyl, haloalkenyl, nitro, cyano, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, heterocyclyl, heterocyclylalkyl, -OR⁷, -C(O)OR⁷, -C(O)N(R⁷)₂, -N(R⁷)₂, -N(R⁷)C(O)N(R⁷)₂, -N(R⁷)C(O)OR⁸, -N(R⁷)C(O)R⁷, -R⁹-N=N-O-R⁸, -S(O)_pR⁷ (where p is 0 to 2), and -S(O)_pN(R⁷)₂ (where p is 0 to 2);

R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkenyl and heterocyclylalkyl;

each R⁷ is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl;

each R⁸ is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl and cycloalkylalkenyl; and

R⁹ is a bond or a straight or branched alkylene or alkenylene chain; as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or as a solvate or polymorph; or as a pharmaceutically acceptable salt thereof, wherein the method comprises administering the compound of formula (I) to a mammalian cell and the compound of formula (I) is capable of inhibiting the activity of SGK within the mammalian cell.

48. (Original) The method of Claim 47 wherein the mammalian cell is treated in vitro.

49. (Original) The method of Claim 47 wherein the mammalian cell is treated in vivo.

50. (Original) The method of Claim 47 wherein the inhibition of activity results in a reduction of cell survival.

51. (Original) The method of Claim 47 wherein the inhibition of activity results in a reduction of cell division.

52. (Original) The method of Claim 47, wherein the inhibition of activity results in apoptosis.

53. (Original) The method of Claim 47, wherein the inhibition of activity results in control of tumour growth.

54. (Currently Amended) The method or pharmaceutical composition of ~~any one of Claims 1, 40-53~~ Claim 1 or Claim 40 wherein R¹ is carbocyclyl.

55. (Currently Amended) The method or pharmaceutical composition of ~~Claim 54~~ Claim 1 or Claim 40 wherein R¹ is aryl.

56. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~Claim 54~~ wherein R¹ is cycloalkyl.

57. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-53~~ wherein R¹ is heterocyclyl.

58. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R² is hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkylalkenyl.

59. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R² is aryl, aralkyl or aralkenyl.

60. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R² is halo, haloalkyl or haloalkenyl.

61. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R^2 is nitro, cyano, $-N(R^7)_2$, $-N(R^7)C(O)OR^8$, $-N(R^7)C(O)R^7$ or $-R^9-N=N-O-R^8$.

62. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R^2 is heterocyclyl or heterocyclylalkyl.

63. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R^2 is $-C(O)OR^7$ or $-C(O)N(R^7)_2$.

64. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-57~~ wherein at least one R^2 is $-OR^7$, $-S(O)_pR^7$ (where p is 0 to 2), or $-S(O)_pN(R^7)_2$ (where p is 0 to 2).

65. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl or cycloalkylalkenyl.

66. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is aryl, aralkyl or aralkenyl.

67. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is nitro, cyano, $-N(R^7)_2$, $-N(R^7)C(O)OR^8$, $-N(R^7)C(O)R^7$ or $-R^9-N=N-O-R^8$.

68. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is heterocyclyl or heterocyclalkyl.

69. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is $-C(O)OR^7$ or $-C(O)N(R^7)_2$.

70. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-64~~ wherein R^3 is $-OR^7$, $-S(O)_pR^7$ (where p is 0 to 2) or $-S(O)_pN(R^7)_2$ (where p is 0 to 2).

71. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cycloalkyl, cycloalkylalkyl or cycloalkylalkenyl.

72. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is aryl, aralkyl or aralkenyl.

73. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is nitro, cyano, $-N(R^7)_2$, $-N(R^7)C(O)OR^8$, $-N(R^7)C(O)R^7$ or $-R^9-N=N-O-R^8$.

74. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is heterocyclyl or heterocyclalkyl.

75. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is $-C(O)OR^7$ or $-C(O)N(R^7)_2$.

Express Mail No. EV335612620US
International Application No.: PCT/CA2003/000975
International Filing Date: June 25, 2003
Preliminary Amendment

76. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-70~~ wherein R^4 is $-OR^7$, $-S(O)_pR^7$ (where p is 0 to 2) or $-S(O)_pN(R^7)_2$ (where p is 0 to 2).

77. (Currently Amended) The method or pharmaceutical composition of Claim 1 or Claim 40 ~~any one of Claims 1, 40-76~~ wherein R^5 and R^6 are each independently selected from the group consisting of hydrogen, alkyl or haloalkyl.